We explore examples of how CYPA inhibition may be exploited to selectively kill cancers sharing characteristic genomic instability profiles, including MYCN-driven Neuroblastoma, Multiple Myeloma and Chronic Myelogenous Leukaemia. This evidence concerns the gene MYCN and chronic myelogenous leukemia, BCR-ABL1 positive.